Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvirin (2012/2013) Safety and Immunogenicity in Adults and Elderly
NCT01640327Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2012
- Primary completion
- Aug 2012
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Influenza A virus hemagglutinin antigen (A/Uruguay/716/2007 H3N2) in influenza, sponsored by Novartis. Primary endpoints: Percentage of Subjects With Seroconversion or Significant Increase in HI Titer Against Each of Three Vaccine Strains at Day 22, Geometric Mean Ratio of Subjects Against Each of Three Vaccine Strains at Day 22 and 1 more. Started Jul 2012; status: completed.
02
Drugs
Influenza A virus hemagglutinin antigen (A/Uruguay/716/2007 H3N2)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01640327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01640327.